Is taking neratinib/neratinib an overtreatment?

Neratinib/Neratinib is a potent irreversible tyrosine kinase inhibitor that inhibits tumor growth and metastasis by blocking the transduction of the pan-HER family and downstream signaling pathways. For adult patients with HER2-positive early-stage breast cancer, neratinib can be used as an intensified adjuvant therapy after receiving trastuzumab-containing adjuvant therapy. Therefore, whether taking neratinib is excessive treatment needs to be judged based on the patient's condition and the doctor's advice.

The efficacy of neratinib has been verified by multiple clinical trials and has been proven to reduce the risk of breast cancer recurrence. For patients with HER2-positive breast cancer, even after standard adjuvant treatment with trastuzumab, some patients are still at risk of recurrence. Therefore, intensive adjuvant therapy with neratinib is reasonable for these patients. Overtreatment refers to excessive or unnecessary treatment of patients without sufficient evidence to support it. This situation may cause patients to suffer unnecessary side effects and burden, as well as increase medical costs and waste of resources.

Whether a patient can use neratinib for intensive adjuvant treatment needs to be determined based on the patient's condition, including the patient's age, physical condition, tumor stage, pathological type, and whether there are high-risk factors. If the patient's disease is stable and there is no significant risk of recurrence, then intensive adjuvant therapy may not be necessary. Therefore, before deciding whether to use neratinib, a thorough evaluation and discussion should be conducted to ensure the rationality and safety of the treatment.

In addition, neratinib/Neratinib also has some adverse reactions, such as diarrhea, nausea, abdominal pain, etc. These adverse reactions may have a certain impact on patients' quality of life. Therefore, when using neratinib/neratinib, it is necessary to pay close attention to the patient's response and take appropriate measures to mitigate adverse reactions.